Pembrolizumab As First Line Therapy For Metastatic Non Small Cell Lung Cancer

The change from an accelerated to a regular approval was based on the findings of a large phase 3 trial that included more than 600 patients with.

Pembrolizumab as first line therapy for metastatic non small cell lung cancer.

First line therapy for advanced non small cell lung cancer nsclc that lacks targetable mutations is platinum based chemotherapy. Plos one 2017. First line pembrolizumab monotherapy improves overall and progression free survival in patients with untreated metastatic non small cell lung cancer with a programmed death ligand 1 pd l1 tumour proportion score tps of 50 or greater. Non small cell lung cancer nsclc is the most common type of lung cancer accounting for about 85 of all cases.

This review describes trials evaluating the monoclonal antibody pembrolizumab an immunotherapy that blocks the interaction between programmed death 1 and programmed death ligand 1 and 2 pd l1 pd l2 as first line therapy for advanced non small cell lung cancer nsclc. Small cell lung cancer sclc accounts for about 10 to 15 of all lung. Non small cell lung cancer nsclc 80 85 of all lung cancers continues to be one of the major causes of cancer related deaths around the world for the vast majority of patients with advanced or metastatic disease 40 50 of all patients at time of diagnosis platinum based chemotherapy remains the only potential treatment and has led to significantly improved survival outcomes with a. On august 20 2018 fda granted pembrolizumab keytruda regular approval for the initial or first line treatment of patients with metastatic non small cell lung cancer nsclc whose tumors do not have mutations in the egfr or alk genes.

A systematic review of recently published studies. We investigated overall survival after treatment with pembrolizumab monotherapy in patients with a pd l1 tps of 1 or greater. Each year more people die of lung cancer than die of colon and breast cancers combined. Real world treatment patterns for patients receiving second line and third line treatment for advanced non small cell lung cancer.

Standard first line therapy for metastatic squamous non small cell lung cancer nsclc is platinum based chemotherapy or pembrolizumab for patients with programmed death ligand 1 pd l1.